Monday
06.14.2021
10:09 PM
Login form
Search
Calendar
Entries archive

My site

Main » 2020 » June » 15

− Positive Phase 3 Data Evaluating NINLARO as a Maintenance Therapy (TOURMALINE-MM4) Shows Significant Improvement in Progression-Free Survival in Adult Patients Not Treated with Stem Cell Transplantation

− Real-World Community-Based Trial (US MM-6) Results Show Deepening of Responses and Favorable Safety Profile in Transition from Parenteral Bortezomib to Oral NINLARO-Based Treatment

− Oral Presentations Among 12 Takeda-Sponsored Abstracts on NINLARO / Multiple Myeloma to be Highlighted at the 25th Congress of the European Hematology Association (EHA)

 

CAMBRIDGE, Mass. & OSAKA, Japan-Sunday 14 June 2020 [ AETOS Wire ]

(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced it will orally present the results of two studies at the 25th Congress of the European Hematology Association (EHA). Presentations are available online starting Friday, June 12, 2020, an ... Read more »

Views: 29 | Added by: africa-live | Date: 06.15.2020 | Comments (0)